Literature DB >> 21104265

The role of cytokines in Guillain-Barré syndrome.

Ming-Ou Lu1, Jie Zhu.   

Abstract

Cytokines play an important role in the pathogenesis of autoimmune diseases including Guillain-Barré syndrome (GBS) and its animal model experimental autoimmune neuritis (EAN). In this article, we reviewed the current knowledge of the role of cytokines such as TNF-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-23, IL-17, IL-10, IL-4 and chemokines in GBS and EAN as unraveled by studies both in the clinic and the laboratory. However, these studies occasionally yield conflicting results, highlighting the complex role that cytokines play in the disease process. Efforts to modulate cytokine function in GBS and other autoimmune disease have shown efficiency indicating that cytokines are important therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104265     DOI: 10.1007/s00415-010-5836-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  180 in total

1.  Suppression of autoimmune neuritis in IFN-gamma receptor-deficient mice.

Authors:  Y Zhu; H G Ljunggren; E Mix; H L Li; P van der Meide; A M Elhassan; B Winblad; J Zhu
Journal:  Exp Neurol       Date:  2001-06       Impact factor: 5.330

2.  Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system.

Authors:  Iftach Shaked; Ziv Porat; Roman Gersner; Jonathan Kipnis; Michal Schwartz
Journal:  J Neuroimmunol       Date:  2004-01       Impact factor: 3.478

3.  IL-18 deficiency inhibits both Th1 and Th2 cytokine production but not the clinical symptoms in experimental autoimmune neuritis.

Authors:  Rui-Sheng Duan; Xing-Mei Zhang; Eilhard Mix; Hernan Concha Quezada; Abdu Adem; Jie Zhu
Journal:  J Neuroimmunol       Date:  2007-01-09       Impact factor: 3.478

Review 4.  Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis.

Authors:  Jorge A Roman-Blas; Sergio A Jimenez
Journal:  Int Rev Immunol       Date:  2008       Impact factor: 5.311

Review 5.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

Authors:  Karl-Josef Kallen
Journal:  Biochim Biophys Acta       Date:  2002-11-11

6.  I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.

Authors:  M K Sharief; D A Ingram; M Swash; E J Thompson
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

7.  T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation.

Authors:  Ming O Li; Yisong Y Wan; Richard A Flavell
Journal:  Immunity       Date:  2007-05-03       Impact factor: 31.745

8.  Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease.

Authors:  Corinna F Brereton; Caroline E Sutton; Stephen J Lalor; Ed C Lavelle; Kingston H G Mills
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

9.  Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury.

Authors:  W Marie Campana; Xiaoqing Li; Veronica I Shubayev; Mila Angert; Karen Cai; Robert R Myers
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

10.  Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome.

Authors:  K-M Myhr; K S Vågnes; T H Marøy; J H Aarseth; H I Nyland; C A Vedeler
Journal:  J Neuroimmunol       Date:  2003-06       Impact factor: 3.478

View more
  33 in total

1.  Cdc42 GTPases facilitate TNF-α-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells.

Authors:  Kelly A Langert; Cynthia L Von Zee; Evan B Stubbs
Journal:  J Peripher Nerv Syst       Date:  2013-09       Impact factor: 3.494

2.  Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis.

Authors:  Hhoonisha Ramkalawan; Yu-Zhong Wang; Ameet Hurbungs; Yan-Fang Yang; Fa-Fa Tian; Wen-Bin Zhou; Jing Li; Huan Yang; Bo Xiao; Wei Zhang
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

3.  α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro.

Authors:  Nejla Yosef; Eroboghene E Ubogu
Journal:  J Cell Physiol       Date:  2012-12       Impact factor: 6.384

4.  Upregulation of N-Type Voltage-Gated Calcium Channels Induces Neuropathic Pain in Experimental Autoimmune Neuritis.

Authors:  Mei Mao; Wen Fan; Yan Zheng; Pan Qi; Min Xi; Yuanrong Yao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-15       Impact factor: 2.650

Review 5.  The role of chemokines in Guillain-Barré syndrome.

Authors:  Sharon Chiang; Eroboghene E Ubogu
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

6.  Translational strategies in peripheral neuroinflammation and neurovascular repair.

Authors:  Eroboghene E Ubogu
Journal:  Transl Neurosci       Date:  2012-12-01       Impact factor: 1.757

7.  Erythropoietin and autoimmune neuroinflammation: lessons from experimental autoimmune encephalomyelitis and experimental autoimmune neuritis.

Authors:  Taekyun Shin; Meejung Ahn; Changjong Moon; Seungjoon Kim
Journal:  Anat Cell Biol       Date:  2012-12-14

8.  Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cells.

Authors:  Kelly A Langert; Cynthia L Von Zee; Evan B Stubbs
Journal:  ASN Neuro       Date:  2013-02-06       Impact factor: 4.146

Review 9.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

10.  IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.

Authors:  Shujuan Li; Ming Yu; Haifeng Li; Hongliang Zhang; Yanfang Jiang
Journal:  Mediators Inflamm       Date:  2012-10-02       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.